Oroxylin A reverses SHP-2 oxidative inactivation in GPVI signaling to suppress platelet activation and thrombus formation
OroA inhibits platelet activation, thrombus formation and myocardial injury via reversing SHP-2 oxidative inactivation thereby attenuating collagen-induced GPVI signaling. With minor bleeding risk and no obvious pharmacological toxicity, OroA holds promising therapeutic potential as an antithrombotic drug.
Authors
- B Li (ORCID: https://orcid.org/0009-0008-0709-1802)
- Yufei Chen (ORCID: https://orcid.org/0000-0002-4346-6391)
- Jin Tae Hong (ORCID: https://orcid.org/0000-0002-6534-9575)
- Zixian Liu (ORCID: https://orcid.org/0000-0002-3870-4041)
- Deyu Fu (ORCID: https://orcid.org/0000-0002-4678-8564)
- Meiling Wu (ORCID: https://orcid.org/0000-0002-2654-4896)
- Yuan Lin (ORCID: https://orcid.org/0009-0002-2321-8881)
- Jiaorui Wang
- Liang Hu (ORCID: https://orcid.org/0000-0001-5559-3913)
- Jian Li (ORCID: https://orcid.org/0000-0001-7953-8230)
- Mingjie Li (ORCID: https://orcid.org/0000-0003-0417-5089)
- Shufang Wang (ORCID: https://orcid.org/0000-0001-5768-9687)
- Mingzhu Wang (ORCID: https://orcid.org/0000-0003-1361-1540)
- Yongbo Ma (ORCID: https://orcid.org/0009-0009-2676-3923)
- Sun Xiao-lan
Institutions
- Chinese University of Hong Kong (HK)
- Fudan University (CN)
- Shanghai University of Traditional Chinese Medicine (CN)
- Yueyang Hospital (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
- Huashan Hospital (CN)
- University of Hong Kong (HK)
Publication Details
- Journal
- Thrombosis Journal
- Published
- 2025-03-18
- DOI
- https://doi.org/10.1186/s12959-025-00709-9
- Citations
- 2
- Primary Topic
- Antiplatelet Therapy and Cardiovascular Diseases
- Type
- article
- Field-Weighted Citation Impact
- 2.78
Funders
- National Natural Science Foundation of China